Global Cord Blood Corporation
Global Cord Blood Corporation Fundamental Analysis
Global Cord Blood Corporation (CORBF) shows moderate financial fundamentals with a PE ratio of 1.75, profit margin of 40.30%, and ROE of 10.82%. The company generates $1.4B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 78.9/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze CORBF's fundamental strength across five key dimensions:
Efficiency Score
WeakCORBF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCORBF trades at attractive valuation levels.
Growth Score
ModerateCORBF shows steady but slowing expansion.
Financial Health Score
ExcellentCORBF maintains a strong and stable balance sheet.
Profitability Score
ModerateCORBF maintains healthy but balanced margins.
Key Financial Metrics
Is CORBF Expensive or Cheap?
P/E Ratio
CORBF trades at 1.75 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CORBF's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Global Cord Blood Corporation at 0.18 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 11.61 times EBITDA. This signals the market has high growth expectations.
How Well Does CORBF Make Money?
Net Profit Margin
For every $100 in sales, Global Cord Blood Corporation keeps $40.30 as profit after all expenses.
Operating Margin
Core operations generate 48.97 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $10.82 in profit for every $100 of shareholder equity.
ROA
Global Cord Blood Corporation generates $5.87 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Global Cord Blood Corporation generates strong operating cash flow of $676.02M, reflecting robust business health.
Free Cash Flow
Global Cord Blood Corporation generates strong free cash flow of $654.22M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $4.89 in free cash annually.
FCF Yield
CORBF converts 61.37% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
1.75
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.003
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.18
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.78
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
10.73
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.11
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.08
vs 25 benchmark
How CORBF Stacks Against Its Sector Peers
| Metric | CORBF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 1.75 | 28.45 | Better (Cheaper) |
| ROE | 10.82% | 763.00% | Weak |
| Net Margin | 40.30% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 10.73 | 2795.60 | Strong Liquidity |
| ROA | 5.87% | -16588.00% (disorted) | Weak |
CORBF outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Global Cord Blood Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation